SGN — Solgenics Share Price
Last trade - 00:00- £1.08m
- £5.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.1 | ||
| Price to Tang. Book | 0.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.88% | ||
| Return on Equity | -15.23% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Solgenics Limited is a British Virgin Islands-based power supply solutions company. The Company delivers electricity in Africa. The Company is focused on the development of grid scale renewable energy projects in the southern African region by utilizing the sustainable technologies. The Company’s projects are Tete Solar Project, and Benguerra Island Project. The Tete Solar Project is a large scale 300 megawatts (MW) solar photovoltaics plus battery energy system (BESS) development project located in the Tete Province in northern Mozambique. The Benguerra Island Project is a 400 kilowatt 'peak (kWp), fully off-grid solar PV and BESS system installed on the remote island of Bengurra off the coast of mainland Mozambique.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- March 30th, 2006
- Public Since
- June 10th, 2010
- No. of Employees
- 3
- Sector
- Electric Utilities & IPPs
- Industry
- Utilities
- Exchange
- London Stock Exchange
- Shares in Issue
- 566,501,146
- Address
- Sydney Vane House, Admiral Park, TORTOLA, VG1130
- Web
- http://www.ncondezienergy.com/
- Phone
- Contact
- Elizabeth Johnson
- Auditors
- BDO LLP
Latest News for SGN
Upcoming Events for SGN
Similar to SGN
Ignitis Grupe AB
London Stock Exchange
China Yangtze Power Co
London Stock Exchange
Drax
London Stock Exchange
Good Energy
London Stock Exchange
Greencoat Renewables
London Stock Exchange
FAQ
As of Today at 01:20 UTC, shares in Solgenics are trading at 0.19p. This share price information is delayed by 15 minutes.
Shares in Solgenics last closed at 0.19p and the price had moved by -77.65% over the past 365 days. In terms of relative price strength the Solgenics share price has underperformed the FTSE All Share Index by -77.49% over the past year.
The overall consensus recommendation for Solgenics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Solgenics does not currently pay a dividend.
Solgenics does not currently pay a dividend.
Solgenics does not currently pay a dividend.
To buy shares in Solgenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 0.19p, shares in Solgenics had a market capitalisation of £1.08m.
Here are the trading details for Solgenics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SGN
Based on an overall assessment of its quality, value and momentum Solgenics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Solgenics is 15.00p. That is 7794.74% above the last closing price of 0.19p.
Analysts covering Solgenics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Solgenics. Over the past six months, its share price has underperformed the FTSE All Share Index by -73.47%.
As of the last closing price of 0.19p, shares in Solgenics were trading -75.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Solgenics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.19p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Solgenics' management team is headed by:
- Michael Haworth - NEC
- Hanno Pengilly - CEO
- Scott Fletcher - NID
- Aman Sachdeva - NID